Systemic sclerosis A. clinical features

Primer on the Rheumatic Diseases: Thirteenth Edition

Volumn , Issue , 2008, Pages 343-350

  Mayes, Maureen D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892191861     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-68566-3_17     Document Type: Chapter

References (28)

1. Piette WW. Morphea or localized scleroderma. In: Clements PJ, Furst DE, eds. Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004:29-37.
2. Medsger TA Jr. Classification, prognosis. In: Clements PJ, Furst DE, eds. Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004:17-28.
3. Korn JH. Pathogenesis of systemic sclerosis. In: Koopman WJ, Moreland LW, eds. Arthritis and allied conditions. Philadelphia: Lippincott Williams & Wilkins; 2005:1621-1632.
4. Boin F, Wigley FM. Understanding, assessing and treating Raynaud's phenomenon. Curr Opin Rheumatol 2005;17: 752-760.
5. Fraenkel L, Zhang Y, Chaisson CE, et al. Different factors influencing the expression of Raynaud's phenomenon in men and women. Arthritis Rheum 1999;42:306-310.
6. Suter LG, Murabito JM, Felson DT, Fraenkel L. The incidence and natural history of Raynaud's phenomenon in the community. Arthritis Rheum 2005;52:1259-1263.
7. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590.
8. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets, and pathogen-esis. J Rheumatol 1988;15:202-205.
9. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-2444.
10. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma: development of a simplet model using three disease factors at first visit. Arthritis Rheum 1999;42:2660-2665.
11. Cepeda EJ, Reveille JD. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 2004;16:723-732.
12. Clements PJ, Medsger TA Jr, Feghali CA. Cutaneous involvement in systemic sclerosis. In: Clements PJ, Furst DE, eds. Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004:129-150.
13. Poormoghim H, Lucas M, Fertig N, Medsger TA Jr. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000;43:444-451.
14. Weinstein WM, Kadell BM. The gastrointestinal tract in systemic sclerosis. In: Clements PJ, Furst DE, eds. Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004:293-308.
15. Goldblatt F, Gordon TP, Waterman SA. Antibody-mediated gastrointestinal dysmotility in scleroderma. Gastroenterology 2002;123:1144-1150.
16. Mackey RI. Autoimmunity and primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 2000;14:519-533.
17. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2003;30:2398-2405.
18. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005;52:3792-3800.
19. Mukerjee D, St George D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1088-1093.
20. Wigley FM, Lima JAC, Mayes M, McLain D, Chapin JL, Ward-Able C. The UNCOVER study: prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary healthcare level of community-based rheumatologists. Arthritis Rheum 2005;52:2125-2132.
21. Chang B, Wigley FM, White B, Wise RA. Scleroderma patients with combined pulmonary hypertension and interstitial lung disease. J Rheumatol 2006;33:269-274.
22. Follansbee WP, Marroquin OC. Cardiac involvement in systemic sclerosis. In: Clements PJ, Furst DE, eds. Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004:195-220.
23. Smith JW, Clements PJ, Levisman J, Furst D, Ross M. Echocardiographic features of progressive systemic sclerosis (PSS): correlation with hemodynamic and postmortem studies. Am J Med 1979;66:28-33.
24. Steen VD. Renal involvement in systemic sclerosis. In: Clements PJ, Furst DE, eds. Systemic sclerosis. Philadelphia: Lippincott Williams & Wilkins; 2004:279-292.
25. Pope JE. Musculoskeletal involvement in scleroderma. Rheum Dis Clin North Am 2003;52:391-405.
26. Clements PJ, Furst DE, Campion DS, et al. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic consideration. Arthritis Rheum 1978;21:62-71.
27. Mori Y, Kahari VM, Varga J. Scleroderma-like cutaneous syndromes. Curr Rheumatol Rep 2002;4:113-122.
28. Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. Curr Rheumatol Rep 2006;8:151-157.